As of 14 Oct 2026, Rakuten Medical has raised $100M across 1 verified round on record; latest: $100 million Series F led by TaiAx Life Science Fund, announced 7 Jan 2026.
Rakuten Medical develops cancer therapies based on the Alluminox® platform, aimed at treating various cancers.
rakuten-med.comLinkedInSan Diego, United States
1 source
The financing includes $70 million of new capital and the conversion of $30 million in convertible promissory notes plus accrued interest. Existing investors SBI Group, Rakuten Group, and Mickey Mikitani are named separately and excluded from this round’s investor list.; not on the page it cites, so not applied: date
Published by hand (pulse2.com): "Rakuten Medical has closed a $100 million oversubscribed Series F financing to support a global Phase 3 program for its lead investigational therapy ASP-1929.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series F [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-01-07 | TaiAx Life Science Fund | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
The financing includes $70 million of new capital and the conversion of $30 million in convertible promissory notes plus accrued interest. Existing investors SBI Group, Rakuten Group, and Mickey Mikitani are named separately and excluded from this round’s investor list.; not on the page it cites, so not applied: date Published by hand (pulse2.com): "Rakuten Medical has closed a $100 million oversubscribed Series F financing to support a global Phase 3 program for its lead investigational therapy ASP-1929.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it | ||||